Takeaways: BeOne Medicines has cleared the key reimbursement hurdles in Canada for TEVIMBRA + gemcitabine/cisplatin as the first publicly funded first-line immunotherapy for recurrent/metas...
Takeaways: Quaebec’s reimbursement of Vanflyta is a pivotal step toward pan‑Canadian access for a high‑value, biomarker‑targeted AML therapy. Market-wise, public funding acr...
Takeaways: Gazyva’s reimbursement recommendation is a clear commercial win for Roche because it opens the door to public coverage in a high-need, specialty autoimmune market...
Takeaways: Fabhalta gives Novartis a first‑in‑class, oral, mechanism‑targeted therapy in a tiny but high‑need C3G population, creating a premium niche nephrology revenue stream anchored on...
